Literature DB >> 27402817

Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.

Phanthaboon Wangpatharawanit1, Somnuek Sungkanuparph1.   

Abstract

A randomized controlled trial was conducted among human immunodeficiency virus-infected patients receiving lopinavir/ritonavir-based regimens with hypercholesterolemia. Reduction of total cholesterol and low-density lipoprotein was significantly greater in patients who were randomized to the addition of atorvastatin compared with those who were switched from lopinavir/ritonavir to atazanavir/ritonavir.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  atazanavir; atorvastatin; hypercholesterolemia; lopinavir; randomized controlled trial

Mesh：

Substances：

Year:  2016        PMID： 27402817     DOI： 10.1093/cid/ciw395

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  6 in total

Review 1.  Benefits and Risks of Statin Therapy in the HIV-Infected Population.

Authors:  Mosepele Mosepele; Onkabetse J Molefe-Baikai; Steven K Grinspoon; Virginia A Triant
Journal:  Curr Infect Dis Rep       Date:  2018-05-26       Impact factor: 3.725

2.  Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy.

Authors:  Daisuke Mizushima; Nguyen Thi Hoai Dung; Nguyen Thi Dung; Shoko Matsumoto; Junko Tanuma; Hiroyuki Gatanaga; Nguyen Vu Trung; Nguyen Van Kinh; Shinichi Oka
Journal:  Glob Health Med       Date:  2020-02-29

3.  Evaluation of Oral Antiretroviral Drugs in Mice With Metabolic and Neurologic Complications.

Authors:  Fuu-Jen Tsai; Mao-Wang Ho; Chih-Ho Lai; Chen-Hsing Chou; Ju-Pi Li; Chi-Fung Cheng; Yang-Chang Wu; Xiang Liu; Hsinyi Tsang; Ting-Hsu Lin; Chiu-Chu Liao; Shao-Mei Huang; Jung-Chun Lin; Chih-Chien Lin; Ching-Liang Hsieh; Wen-Miin Liang; Ying-Ju Lin
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

4.  Switching protease inhibitors to rilpivirine in HIV-positive individuals with complete viral suppression and without prior HIV drug resistance in a resource-limited setting: a randomized controlled trial.

Authors:  Kulissara Palanuphap; Somnuek Sungkanuparph
Journal:  J Int AIDS Soc       Date:  2020-04       Impact factor: 5.396

Review 5.  Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019.

Authors:  Wenyi Peng; Hao Wu; Yan Tan; Mei Li; Dachun Yang; Shuang Li
Journal:  Life Sci       Date:  2020-09-25       Impact factor: 5.037

6.  Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.

Authors:  Simeon Eche; Ajit Kumar; Nelson Sonela; Michelle L Gordon
Journal:  Biomolecules       Date:  2021-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.